Here are some of the big stock movers on Friday, as the broader stock market sells off in the wake of worrisome inflation data. Boeing Co.’s stock
BA,
-4.72%
slumped 4.1% in morning trading, enough to pace the Dow Jones Industrial Average’s
DJIA,
-1.14%
decliners, as the airplane maker halted deliveries of the 787 Dreamliner. The Federal Aviation Administration said deliveries are temporarily halted as Boeing is conducting additional analysis on a fuselage component.
Autodesk Inc. shares
ADSK,
-10.82%
tumbled 10.5% to lead the S&P 500 index’s
SPX,
-1.26%
losers, after the enterprise software company provided downbeat first-quarter and full-year profit outlooks, which overshadowed a fourth-quarter profit beat. Shares of Live Nation Entertainment Inc.
LYV,
-9.92%
were the S&P 500’s next-biggest decliners, falling 10.4% after the events promoter reported a wider-than-expected fourth-quarter loss, while revenue beat forecasts. Meanwhile, the Dow sank 502 points, or 1.5%, and the S&P 500 shed 1.75. Among some gainers, Beyond Meat Inc. shares
BYND,
+13.02%
jumped 25.3% toward a 5 1/2-month high, after reporting a narrower-than-forecast loss. Analysts at Mizuho Securities USA say a new strategy, that narrows to channels and segments resonating the most with consumers, may build a better foundation for multi-year revenue growth. Block Inc. shares
SQ,
+2.95%
rose 2.1% as the payments company previously named Square forecast earnings in line with Wall Street estimates. Shares of Turning Point Brands Inc.
TPB,
+5.09%
climbed 4.8% after maker of Zig-Zag rolling paper reported fourth-quarter profit and revenue that beat expectations. Sweetgreen Inc. shares
SG,
+1.94%
slumped 2.7% after the salad-focused fast-food chain reported a fourth-quarter loss that was wider than analyst estimates and guided for revenue below Wall Street estimates. Elsewhere, Nektar Therapeutics’ stock
NKTR,
-46.62%
plummeted 44.2% after a lupus study failed to meet its primary endpoint, and the company said that partner Eli Lilly & Co.
LLY,
-1.78%
would not proceed with a Phase 3 study, while Sellas Life Sciences Group Inc.’s stock
SLS,
-53.66%
plunged 55.4% to lead the Nasdaq exchange’s losers after the biopharmaceutical company announced a public offering of common stock and warrants to buy shares. Cingulate Inc.’s stock
CING,
+50.65%
rocketed 46.3% after the biopharmaceutical company reported positive results from a trial of its attention deficit/hyperactivity disorder (ADHD) treatment.
…